The CDTI SICC Innvierte of investing in Innovation Ona Pharmaceuticals, together with five coinversores, to develop new innovative therapies using ADCs that attack cancer advanced

Ona Pharmaceuticals is a pioneer in the development of joint anticuerpo-fármaco (ADC) that take advantage of the molecular basis of advanced cancer. It focuses, through collaboration with academic and medical experts, in providing effective new treatments for patients without alternatives.

Cancer patients tend to be advanced multi-processing lines and often there are no longer other options. A key challenge lies in the limited understanding of how the cancer develops along the lines of treatment, hampering identification of new targets therapeutic therapeutic potential.

This company aspires to new therapies with unprecedented effectiveness thanks to a profound understanding of the cancer biology refractory and plasticity. By adding real samples refractory of patients, identify how the standard treatment transforms cancer at the molecular level. This strategy enables Ona Pharmaceuticals therapeutic identify targets beyond the traditional tumour antigens and define new stocks of patients where these therapies will be highly effective.

The CDTI Innovation, through Innvierte, has closed an operation of investment in this endeavour with Asabys Partners (through its funds SABADELL ASABYS HEALTH INNOVATION INVESTMENTS, S.C.R., S.A., ASABYS TOP UP FUND, RCF), Ysios Capital Partners (through YSIOS BIOFUND III, FCRE), FCRE, HIGH LIFE SCIENCES SPAIN I RCF and FUNDPLUS NV, with a sum of eur 10,000,000 investment. This participation, the CDTI Innovation contributes to the creation of BC and therapies antibodies, with the goal of providing effective new treatments for cancer patients, so far without alternatives.

Asabys Partners

Asabys Partners is a risk capital based in Barcelona, focusing on innovation in health and life sciences, including biofarma, health and medical technology. The digital signature, founded in 2018 by Josep Ll. Sanfeliu Campàs and clear, is targeted at supporting innovative technologies and transformative addressing unmet medical needs. Asabys manages eur 400 million in assets and has invested in about 25 companies. Asabys invested in Ona Pharmaceuticals fund since its first composed of SABADELL ASABYS HEALTH INNOVATION INVESTMENTS, S.C.R., S.A. and ASABYS TOP UP FUND, RCF. Asabys is positioned not only as an investor, but as an active partner and friend of his companies owned by the group with the aim of translating scientific disruptive manner in significant results for patients. Asabys co-gestiona with AltamarCAM, the fund HIGH LIFE SCIENCES SPAIN I RCF also Ona Pharmaceuticals investor.

Ysios Capital Partners

Ysios Capital is a spanish leading manager in venture capital which provides funding to enterprises of life sciences that are highly innovative treatments for large indications with unmet medical needs. With offices in San Sebastian and Barcelona, has a team of professionals whose aim is to transform the capital in medical breakthroughs with a positive impact on society. Founded in 2008, manages more than eur 400 million in assets through three funds and also acts as an adviser to the fund's investment of dollar-Telescope Biotech Fund, managed by Andbank Wealth Management. Ysios invested in Ona Pharmaceuticals fund since its third YSIOS BIOFUND III, FCRE.

FUNDPLUS NV (Fund +)

Belgian investment fund invests in innovative companies in the life sciences, mainly dedicated to therapeutic and diagnostic companies and medical devices. Fund + wants to contribute in a sustainable way to the improvement of the ecosystem of biotech companies. To date, it has attracted eur 200 million in funding. Investors are persons with a high heritage, family offices and agencies that share the same long-term vision and the same social values of the founders. The size of the planned investment by business will be between 5 and 15 million euros, distributed in different milestones.

Innvierte

Innvierte is an initiative aimed at promoting the entrepreneurial innovation through support to the risk capital investment in technology-based enterprises or innovative programme. This is done through the collective investment type closed Innvierte Sustainable Economy SICC S.M.E., S.A., self-managed and under the supervision of the national Values and that the CDTI Innovation is a shareholder Only.

To date, the CDTI innovation has committed 2,661 M €in 61 investment vehicles that have invested in more than 622 companies, and through its joint investment line directly committed an amount of 723 M €in 190 firms.

Innvierte fits into the strategy for science, technology and innovation 2021-2027, adopted by decision of the council of ministers, in september. This 2020 Strategy contains goals, the reforms and measures to be taken throughout the area of r + D + i in order to boost their growth and impact, and is one of the pillars on which the design of the government's policy in r + D + i for the coming years.

CDTI Innovation

The centre for technological development and innovation, CDTI E.P.E. is the agency for innovation of the ministry of science, innovation and universities, whose goal is the promotion of technological innovation in business. The CDTI mission is to ensure that the business fabric english generates and transform knowledge into growth científico-técnico globally competitive, sustainable and inclusive. By 2024, within the framework of a new strategic plan, the CDTI provided more than $2.3 billion euros of support for business startups and spain.

Further information,

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
X:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial

Ona Pharmaceuticals:
Website:https :// ona-therapeutics.com/
In LinkedIn:https :// www.linkedin.com/company/ona-therapeutics/

ASABYS PARTNERS SGEIC, S.A.:
Website:https :// asabys.com/
In LinkedIn:https :// www.linkedin.com/company/asabys-partners/
X:https :// x.com/AsabysPartners

YSIOS CAPITAL PARTNERS, SGEIC, S.A.U.:
Website:https :// ysioscapital.com/
In LinkedIn:https :// www.linkedin.com/company/ysios-capital/
X:https :// x.com/YsiosCapital

FUNDPLUS NV (Fund +):
Website:https :// fundplus.be/
In LinkedIn:https :// www.linkedin.com/company/fund-/
X:https :// x.com/Fundplus2

This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (@CDTI _ innovation).